Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

PURPOSE: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to investigate whether enrollment in biomarker-matched earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmagnani Pestana, Roberto, Moyers, Justin T., Roszik, Jason, Sen, Shiraj, Hong, David S., Naing, Aung, Herzog, Cynthia E., Fu, Siqing, Piha-Paul, Sarina A., Rodon, Jordi, Yap, Timothy A., Karp, Daniel D., Tsimberidou, Apostolia M., Pant, Shubham, Zarzour, Maria A., Ratan, Ravin, Ravi, Vinod, Benjamin, Robert S., Lazar, Alexander J., Wang, Wei-Lien, Daw, Najat, Gill, Jonathan B., Harrison, Douglas J., Lewis, Valerae O., Roland, Christina L., Patel, Shreyaskumar R., Livingston, J. Andrew, Somaiah, Neeta, Ludwig, Joseph A., Conley, Anthony P., Hamerschlak, Nelson, Gorlick, Richard, Meric-Bernstam, Funda, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150251/
https://www.ncbi.nlm.nih.gov/pubmed/37058010
http://dx.doi.org/10.1158/1078-0432.CCR-22-3629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150251/
https://www.ncbi.nlm.nih.gov/pubmed/37058010
http://dx.doi.org/10.1158/1078-0432.CCR-22-3629

Ejemplares similares